BMP-2 but not VEGF or PDGF in fibrin matrix supports bone healing in a delayed-union rat model

Martin Kaipel; Sebastian Schützenberger; Arthur Schultz; James Ferguson; Paul Slezak; Tatjana J Morton; Martijn Van Griensven; Heinz Redl

doi:10.1002/jor.22132

BMP-2 but not VEGF or PDGF in fibrin matrix supports bone healing in a delayed-union rat model

Martin Kaipel^*, Sebastian Schützenberger, Arthur Schultz, James Ferguson, Paul Slezak, Tatjana J Morton, Martijn Van Griensven, Heinz Redl

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Treatment of delayed bone healing and non-unions after fractures, osteotomies or arthrodesis still is a relevant clinical challenge. Artificially applied growth factors can increase bone healing and progressively gain importance in clinical routine. The aim of this study was to determine the effects of rhPDGF-BB, rhVEGF-165, and rhBMP-2 in fibrin matrix on bone healing in a delayed-union rat model. Thirty-seven rats underwent a first operation where a standardized femoral critical size defect was created. A silicone spacer was implanted to impair vascularization within the defect. At 4 weeks the spacer was removed in a second operation and rhPDGF-BB, rhVEGF-165, or rhBMP-2 were applied in a fibrin clot. Animals in a fourth group received a fibrin clot without growth factors. At 8 weeks fibrin bound rhBMP-2 treated animals showed a significantly increased union rate and bone volume within the defect compared to the other groups. Single application of fibrin bound rhPDGF-BB and rhVEGF-165 failed to increase bone healing in our atrophic non-union model.

Original language	English
Pages (from-to)	1563-9
Number of pages	7
Journal	Journal of Orthopaedic Research
Volume	30
Issue number	10
DOIs	https://doi.org/10.1002/jor.22132
Publication status	Published - Oct 2012
Externally published	Yes

Keywords

Animals
Bone Morphogenetic Protein 2/pharmacology
Femoral Fractures/drug therapy
Femur/pathology
Fibrin/pharmacokinetics
Fracture Healing/drug effects
Fractures, Ununited/drug therapy
Male
Platelet-Derived Growth Factor/pharmacology
Rats
Rats, Sprague-Dawley
Recombinant Proteins/pharmacology
Vascular Endothelial Growth Factor A/pharmacology

Access to Document

10.1002/jor.22132

Cite this

@article{bc225fc8c7514c19acb6ad2539b3ccf3,

title = "BMP-2 but not VEGF or PDGF in fibrin matrix supports bone healing in a delayed-union rat model",

abstract = "Treatment of delayed bone healing and non-unions after fractures, osteotomies or arthrodesis still is a relevant clinical challenge. Artificially applied growth factors can increase bone healing and progressively gain importance in clinical routine. The aim of this study was to determine the effects of rhPDGF-BB, rhVEGF-165, and rhBMP-2 in fibrin matrix on bone healing in a delayed-union rat model. Thirty-seven rats underwent a first operation where a standardized femoral critical size defect was created. A silicone spacer was implanted to impair vascularization within the defect. At 4 weeks the spacer was removed in a second operation and rhPDGF-BB, rhVEGF-165, or rhBMP-2 were applied in a fibrin clot. Animals in a fourth group received a fibrin clot without growth factors. At 8 weeks fibrin bound rhBMP-2 treated animals showed a significantly increased union rate and bone volume within the defect compared to the other groups. Single application of fibrin bound rhPDGF-BB and rhVEGF-165 failed to increase bone healing in our atrophic non-union model.",

keywords = "Animals, Bone Morphogenetic Protein 2/pharmacology, Femoral Fractures/drug therapy, Femur/pathology, Fibrin/pharmacokinetics, Fracture Healing/drug effects, Fractures, Ununited/drug therapy, Male, Platelet-Derived Growth Factor/pharmacology, Rats, Rats, Sprague-Dawley, Recombinant Proteins/pharmacology, Vascular Endothelial Growth Factor A/pharmacology",

author = "Martin Kaipel and Sebastian Sch{\"u}tzenberger and Arthur Schultz and James Ferguson and Paul Slezak and Morton, {Tatjana J} and {Van Griensven}, Martijn and Heinz Redl",

note = "Copyright {\textcopyright} 2012 Orthopaedic Research Society.",

year = "2012",

month = oct,

doi = "10.1002/jor.22132",

language = "English",

volume = "30",

pages = "1563--9",

journal = "Journal of Orthopaedic Research",

issn = "0736-0266",

publisher = "Wiley",

number = "10",

}

TY - JOUR

T1 - BMP-2 but not VEGF or PDGF in fibrin matrix supports bone healing in a delayed-union rat model

AU - Kaipel, Martin

AU - Schützenberger, Sebastian

AU - Schultz, Arthur

AU - Ferguson, James

AU - Slezak, Paul

AU - Morton, Tatjana J

AU - Van Griensven, Martijn

AU - Redl, Heinz

PY - 2012/10

Y1 - 2012/10

N2 - Treatment of delayed bone healing and non-unions after fractures, osteotomies or arthrodesis still is a relevant clinical challenge. Artificially applied growth factors can increase bone healing and progressively gain importance in clinical routine. The aim of this study was to determine the effects of rhPDGF-BB, rhVEGF-165, and rhBMP-2 in fibrin matrix on bone healing in a delayed-union rat model. Thirty-seven rats underwent a first operation where a standardized femoral critical size defect was created. A silicone spacer was implanted to impair vascularization within the defect. At 4 weeks the spacer was removed in a second operation and rhPDGF-BB, rhVEGF-165, or rhBMP-2 were applied in a fibrin clot. Animals in a fourth group received a fibrin clot without growth factors. At 8 weeks fibrin bound rhBMP-2 treated animals showed a significantly increased union rate and bone volume within the defect compared to the other groups. Single application of fibrin bound rhPDGF-BB and rhVEGF-165 failed to increase bone healing in our atrophic non-union model.

AB - Treatment of delayed bone healing and non-unions after fractures, osteotomies or arthrodesis still is a relevant clinical challenge. Artificially applied growth factors can increase bone healing and progressively gain importance in clinical routine. The aim of this study was to determine the effects of rhPDGF-BB, rhVEGF-165, and rhBMP-2 in fibrin matrix on bone healing in a delayed-union rat model. Thirty-seven rats underwent a first operation where a standardized femoral critical size defect was created. A silicone spacer was implanted to impair vascularization within the defect. At 4 weeks the spacer was removed in a second operation and rhPDGF-BB, rhVEGF-165, or rhBMP-2 were applied in a fibrin clot. Animals in a fourth group received a fibrin clot without growth factors. At 8 weeks fibrin bound rhBMP-2 treated animals showed a significantly increased union rate and bone volume within the defect compared to the other groups. Single application of fibrin bound rhPDGF-BB and rhVEGF-165 failed to increase bone healing in our atrophic non-union model.

KW - Animals

KW - Bone Morphogenetic Protein 2/pharmacology

KW - Femoral Fractures/drug therapy

KW - Femur/pathology

KW - Fibrin/pharmacokinetics

KW - Fracture Healing/drug effects

KW - Fractures, Ununited/drug therapy

KW - Male

KW - Platelet-Derived Growth Factor/pharmacology

KW - Rats

KW - Rats, Sprague-Dawley

KW - Recombinant Proteins/pharmacology

KW - Vascular Endothelial Growth Factor A/pharmacology

U2 - 10.1002/jor.22132

DO - 10.1002/jor.22132

M3 - Article

C2 - 22508566

SN - 0736-0266

VL - 30

SP - 1563

EP - 1569

JO - Journal of Orthopaedic Research

JF - Journal of Orthopaedic Research

IS - 10

ER -

BMP-2 but not VEGF or PDGF in fibrin matrix supports bone healing in a delayed-union rat model

Abstract

Keywords

Access to Document

Fingerprint

Cite this